Storys zum Thema Pharma

04.06.2015 – 09:07
ITM Isotope Technologies Munich SE
Isotope Technologies Garching announces successful Validation of EndolucinBeta (TM) (n.c.a. Lutetium-177) Marketing Authorization Application by the European Medicines Agency
Garching (ots) - The ITM Group announced today that the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) of the medicinal product EndolucinBeta, a radiopharmaceutical precursor. EndolucinBeta is not intended for direct use in patients but will be used for ...
mehr
27.01.2015 – 13:07
Max Lehner AG
Dersim Stein acquires full ownership of Max Lehner Holding AG
mehr
19.12.2014 – 09:01
AmVac AG
New possibilities in the fight against pancreatic cancer
Zug, Switzerland (ots) - Licence extension in the contract between AmVac and the Helmholtz Centre for the adjuvant Malp-2 offers sustainable potential for patients, attending physicians and for pharmaceutical and medical research. Milestone thanks to licence extension The licence for Malp-2 was successfully extended in November 2014. The adjuvant can now be used for the first time for all preventive and therapeutic ...
mehr
10.11.2014 – 12:00
European Society for Medical Oncology (ESMO)
ESMO announces annual medical oncology congress platform in Europe from 2016
Lugano, Switzerland (ots) - The European Society for Medical Oncology, the pan-European association representing medical oncologists in Europe and beyond, has announced that it will be organising an annual Congress in Europe from 2016. A record 19,809 participants from 134 countries gathered at ESMO 2014 in Madrid to hear the results of trials which included ...
mehr
24.10.2014 – 13:24
Eckert & Ziegler Strahlen und Medizintechnik AG
Eckert & Ziegler awarded contract to produce new type of medicine to fight pancreatic cancer
Berlin (ots) - Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is engaging with a USA based biotech company to become a contract manufacturer for a new type of cancer treatment and is creating a new production plant for this purpose at its Braunschweig location with financial support provided by the customer. The cooperation enfolds a brand-new ...
mehr
06.10.2014 – 14:00
TVM Capital
TVM Life Science Ventures VII Raises US $201.6 Million at Final Closing
Montreal/Munich (ots) - Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest ...
mehr

26.09.2014 – 09:00
Grünenthal GmbH
Improved pain relief for patients with severe chronic low back pain - results of a new study show 37%* more pain relief with Palexia® (tapentadol PR) compared to oxycodone/naloxone PR
Aachen (ots) - EMBARGO: This information is for European healthcare professionals only. Not intended for UK audience. Low back pain is one of the most common chronic pain conditions. Studies have shown that up to 85% of people worldwide will suffer from back pain during their lives.(1) A high percentage of severe ...
mehr
18.09.2014 – 08:00
Sanofi
Sanofi Announces Upcoming Launch of MyStar Connect®
Vienna, Austria (ots) - - MyStar Connect® software contributes to Sanofi's commitment in providing integrated diabetes care solutions, and supports healthcare professionals in clinical decision-making - - CE mark for MyStar Connect® - At the 50th annual meeting of the European Association for the Study of Diabetes (EASD) in Vienna, Austria, Sanofi (EURONEXT: SAN and NYSE: SNY) announced today the upcoming launch of ...
mehr
25.08.2014 – 09:10
Grünenthal GmbH
New Palexia® study confirms effective pain relief in long-term use / Chronic pain patients benefit from long-term tapentadol treatment
Aachen (ots) - - EMBARGO: This information is for healthcare professionals only. Not intended for UK audience. - A recent study published in the medical journal "Current Medical Research and Opinion"* has results that are good news for chronic pain patients. This new trial was designed to meet real-life conditions ...
mehr
26.06.2014 – 14:23
Helsinn Healthcare SA
Eisai Oncology & Helsinn Group to Present New CINV Research at 2014 International Symposium on Supportive Care in Cancer
Woodcliff Lake, NJ, and Lugano, Switzerland (ots) - Eisai Inc. and Helsinn Group announced today that several abstracts highlighting data analyses of NEPA, an investigational oral fixed- dose combination of netupitant and palonosetron being evaluated for the prevention of chemotherapy-induced nausea and vomiting ...
mehr
25.06.2014 – 14:35
Helsinn Healthcare SA
Helsinn Therapeutics (U.S.), Inc. Strengthens its Board of Directors
Lugano, Switzerland (ots) - Helsinn Group, the Company focused on building quality cancer care, announced today the appointment of Dr. Philip S. Schein, to the Board of Directors of its U.S. subsidiary, Helsinn Therapeutics Inc. ("HTU"), effective 8 May 2014. Dr. Philip Schein was the former Founder, Chairman and CEO of US Biosciences, Inc., and Chair of the Clinical Investigations Committee of the National Cancer ...
mehr
08.04.2014 – 10:16
Grünenthal GmbH
Grünenthal and Pain Alliance Europe urge EU and national authorities to improve chronic pain management
Aachen/Brussels (ots) - Multi-stakeholder views on chronic pain presented in the European Parliament / Call to Action to fight chronic pain On the occasion of an exhibition and cocktail reception hosted by Petru Luhan, Member of the European Parliament and winner of the MEP award for Health 2013, a multi- ...
mehr

01.04.2014 – 13:13
Helsinn Healthcare SA
Helsinn promotes the use of mobile technology in cancer supportive care through mobile health
Lugano, Switzerland (ots) - The pharmaceutical group in Ticino, global leader in cancer supportive care, supports the International Conference on mobile technology dedicated to improve the quality of life of people with cancer in collaboration with SDA Bocconi and CERGAS Bocconi. The combination of medicine and mobile technology to improve the quality of life of people ...
mehr
13.03.2014 – 14:00
Helsinn Healthcare SA
Helsinn Named as One of the Best Places to Work in New Jersey by NJBIZ
Bridgewater, New Jersey (ots) - Helsinn Group, the company focused on building quality cancer care, is pleased to announce today that its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc., has been named as one of the 100 best places to work in New Jersey in a survey and award program conducted by NJBIZ which recognizes and honors the state's top employers who show a ...
mehr
29.01.2014 – 15:10
Debiotech S.A.
Debiotech will be introducing its new insulin JewelPUMP2 for Diabetes Type 2 during the 2014 ATTD conference in Vienna, Austria
Lausanne, Switzerland (ots) - - Click here for Picture 1 (http://www.debiotech.com/news/images/nw181_1.png ) The JewelPUMP2, which will be unveiled for the first time at the ATTD 2014 congress on February 5th in Vienna, is a new product dedicated to the Diabetes Type 2 market, based on Debiotech's innovative ...
mehr
29.01.2014 – 12:00
Helsinn Healthcare SA
Helsinn announces European Medicines Agency acceptance of regulatory submission for netupitant-palonosetron fixed dose combination (NEPA)
Lugano, Switzerland (ots) - NEPA is currently under development for the treatment of chemotherapy-induced nausea and vomiting The Swiss pharmaceutical Helsinn Group announced today that on January 22nd the European Medicines Agency (EMA) determined netupitant-palonosetron fixed dose combination (NEPA) Marketing ...
mehr
15.01.2014 – 12:09
Helsinn Healthcare SA
Helsinn Group and Angelini ink an agreement for license rights to phase-III ghrelin receptor agonist Anamorelin in Central & Eastern Europe
Lugano, Schweiz (ots) - Swiss Pharma Group Helsinn grants exclusive distribution and licensing rights to Angelini, through its subsidiary company CSC Pharmaceuticals, for the commercialization in Austria, Bulgaria, Czech Republic, Hungary , Poland, Romania, Slovak Republic, Georgia, Russia and the other CIS ...
mehr
19.12.2013 – 09:30
Takeda Pharmaceuticals International GmbH
Dexlansoprazole, a new dual-delayed release technology for the treatment of reflux disease, accepted for national approvals within the European Union
Zurich Switzerland (ots) - Takeda Pharmaceuticals International GmbH ("Takeda") announced that the European decentralised procedure (DCP) was positively concluded for dexlansoprazole, a proton pump inhibitor (PPI) with a new dual- delayed release technology for the treatment of reflux disease. The regulatory process ...
mehr

19.12.2013 – 08:00
Helsinn Healthcare SA
Swiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
mehr
19.12.2013 – 08:00
Helsinn Healthcare SA
Swiss-based Helsinn Group and Mundipharma sign for rights to Phase III Netupitant-Palonosetron fixed dose combination for China
Lugano, Switzerland (ots) - The two companies sign a distribution and license agreement for an investigational therapy for the prevention of chemotherapy-induced nausea and vomiting covering China, Hong Kong and Macao Helsinn and Mundipharma announce the signature of a new, exclusive license and distribution ...
mehr
18.12.2013 – 12:28
Helsinn Healthcare SA
Helsinn and Italfarmaco reinforce their alliance through the grant of rights to phase-III ghrelin receptor agonist Anamorelin in Italy
Lugano, Switzerland (ots) - Helsinn Group grants exclusive distribution and licensing rights to Italfarmaco for the commercialization of its compound currently in development for the treatment of anorexia-cachexia syndrome related to non-small cell lung cancer (NSCLC) Helsinn Group is pleased to announce that ...
mehr
16.12.2013 – 14:05
Grünenthal GmbH
Grünenthal and AcelRx enter into partnership for EU commercialization of ZALVISO®
Aachen, Germany / Redwood City (California), USA (ots) - Grünenthal Group today announced that the company entered into a commercial partnership with AcelRx Pharmaceuticals, Inc. for ZALVISO, a patient-controlled analgesia device for self- administration of sufentanil nanotablets by patients following surgery. The agreement covers the countries of the European Union, ...
mehr
13.12.2013 – 09:05
European Society for Medical Oncology (ESMO)
Defending Medical Oncology to Assure Quality Care for Cancer Patients / ESMO releases position paper on medical oncologist's role
Lugano (ots) - Medical oncologists have a vital role to play in cancer care, particularly as treatments become ever more complex, a new position statement from the European Society for Medical Oncology says (http://www.presseportal.ch/go2/new_position_statement ). Medical oncologists are specialist cancer physicians ...
mehr
09.12.2013 – 16:29
Helsinn Healthcare SA
Helsinn Group and Eisai announce FDA acceptance of New Drug Application for investigational compound netupitant 300 mg + palonosetron 0.50 mg (NEPA)
Lugano, Switzerland/Woodcliff Lake, NJ, USA (ots) - Seeking indication for prevention of chemotherapy-induced nausea and vomiting Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the submission of the New Drug Application (NDA) for the investigational ...
mehr

03.12.2013 – 11:00
Helsinn Healthcare SA
Helsinn Group's representative office in China: Official inauguration
Lugano, Switzerland - Beijing, PRC (ots) - Helsinn Group, the independent, privately-owned, Swiss pharmaceutical company, with a worldwide presence built over 35 years, lands in China. Helsinn's Representative Office was officially inaugurated in Beijing, PRC yesterday. With headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United ...
mehr
02.12.2013 – 12:23
Debiopharm International SA
BPA Solutions get Investment funds to accelerate rapid growth and global expansion
Yverdon, Switzerland (ots) - BPA Solutions SA (BPA), headquartered at Swiss Technopole Yverdon, Switzerland, today announced it has raised development funds from Debiopharm Investment. BPA is a global leading provider of innovative business software solutions based on Microsoft (MS) SharePoint technologies with 800+ customers and 50+ partners worldwide. Profitable ...
mehr
28.11.2013 – 09:00
European Society for Medical Oncology (ESMO)
Untreated cancer pain a 'scandal of global proportions,' ESMO-led survey shows / New global study reveals a pandemic of intolerable pain affecting billions, caused by pain medicines overregulation
Lugano (ots) - A ground-breaking international survey published today, shows that more than half of the world's population live in countries where regulations aiming to stem drug misuse leave patients without access to opioid medicines for managing cancer pain. The results from the Global Opioid Policy Initiative ...
mehr
12.11.2013 – 04:00
Helsinn Healthcare SA
Helsinn and Chugai Pharma Marketing enter into agreement for rights of Anamorelin,currently in development for treatment of anorexia-cachexia syndrome related to non-small cell lung cancer in top EU markets
Lugano, Switzerland (ots) - Swiss Pharma Group Helsinn seals an alliance with Japanese company Chugai by granting exclusive distribution & licensing rights to commercialize its innovative phase III ghrelin receptor agonist in Germany, France, Benelux, UK and Ireland Swiss-based Helsinn group has granted Chugai ...
mehr
01.10.2013 – 14:32
Helsinn Healthcare SA
Helsinn to launch sales organization in the United States
Lugano, Switzerland (ots) - The Swiss Helsinn Group announced today the formation of a sales organization in the US subsidiary, Helsinn Therapeutics (US) Inc. A commercial organization of 20 people has been engaged throughout the United States. The new oncology sales representatives will be working via a co-detailing agreement for Aloxi® (palonosetron HCl injection), licensed by the Helsinn Group to Eisai, Inc. The ...
mehr
25.09.2013 – 15:00
Sanofi
Sanofi announces upcoming launch of MyStar Extra®, the first self- monitoring blood glucose meter with estimated A1c
Paris (ots) - - CE marks obtained for MyStar Extra® and MyStar SylkFeel® lancing device, respectively, enabling commercialization in the European Union - Scientific data presented at EASD 2013 demonstrate robustness and accuracy[i],[ii] of estimated A1c algorithm in MyStar Extra® At the annual meeting of the ...
mehr

Vorherige12345678910Nächste